Clinical trial
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium…
NCT00081159 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00081159 |
|---|---|
| Title | Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases |
| Official title | A Randomized Phase II Study Of Bone-Targeted Therapy In Advanced Androgen-Dependent Prostate Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Cancer, Prostate Cancer |
| Intervention type | Drug, Procedure, Radiation |
| Interventions | Doxorubicin hydrochloride, Goserelin acetate, Leuprolide acetate, Zoledronic acid, orchiectomy, strontium chloride Sr |
| Enrollment | 80 |
| Start date | Jul 1, 2004 |
| Primary completion | Sep 1, 2014 |
| Completion | Sep 1, 2014 |
| First posted | Apr 8, 2004 |
| Last update posted | Nov 10, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: